Gladys Villas Boas Do Prado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gladys Villas Boas Do Prado has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Anna Sara Levin
Universidade de São Paulo, Brasil
8 shared publications - Thais Guimarães
Infection Control Department, Instituto Central, Hospital das Clínicas, São Paulo, SP, 04517-050, Brazil.
4 shared publications Flavia Rossi
Divisão de Laboratório Central - Serviço de Microbiologia Clínica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
3 shared publications- Maristela Pinheiro Freire
Infectious Diseases Service, Cancer Institute, University of São Paulo School of Medicine, Sao Paulo, Brazil
3 shared publications - Edson Abdala
Universidade de São Paulo
2 shared publications Maura S. Oliveira
Infection Control Department, Hospital das Clinicas, Universidade de São Paulo, SP, Brazil, Infection Control Department, Hospital das Clinicas, Universidade de São Paulo, SP, Brazil
2 shared publications
Latest Publications
- 1 May 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (5)
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays
Susceptibility of ceftazidime-avibactam and in vitro synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant Acinetobacter baumannii isolates harboring oxacillinases and 5 Serratia marcescens isolates carrying bla KPC-2 . Ceftazidime-avibactam was very active and synergistic with meropenem against multiresistant S. marcescens isolates.
- 1 May 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (5)
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays
Susceptibility of ceftazidime-avibactam and in vitro synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant Acinetobacter baumannii isolates harboring oxacillinases and 5 Serratia marcescens isolates carrying bla KPC-2 . Ceftazidime-avibactam was very active and synergistic with meropenem against multiresistant S. marcescens isolates.
- Top Cited Papers
- 1 March 2018
- Published by Elsevier in The Lancet HIV
- Vol. 5 (3) , e136-e145
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study
- 1 March 2018
- Published by Elsevier in The Lancet HIV
- Vol. 5 (3) , e136-e145
Top Cited PapersRetention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study
- 1 April 2016
- Published by Morressier GmbH
Use of ATP bioluminescence to control multidrug resistant organisms at a bone marrow transplant unit
Welcome to the largest platform for early-stage research
- 1 April 2016
- Published by Morressier GmbH
Use of ATP bioluminescence to control multidrug resistant organisms at a bone marrow transplant unit
Welcome to the largest platform for early-stage research
- 1 February 2015
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 21 (2) , 179.e1-179.e7
Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins
- 1 February 2015
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 21 (2) , 179.e1-179.e7
Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins
- 12 April 2014
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (3) , 369-378
Polymyxin use as a risk factor for colonization or infection with polymyxin‐resistant Acinetobacter baumannii after liver transplantation
Introduction Acinetobacter baumannii is a leading agent of healthcare‐associated infection. The objective of this study was to evaluate cases of colonization or infection with polymyxin‐resistant A. baumannii (PRAB) in liver transplant recipients and to identify the risk factors for the acquisition of PRAB. Methods We evaluated all patients undergoing liver transplantation (LT) between January and November of 2011. The exclusion criterion was death within the first 72 h after transplant. Patients were screened for PRAB through weekly rectal and inguinal swabs during their stay in the intensive care unit (ICU) and at ICU discharge. Patients who came from other hospitals or had been treated in the emergency room for >72 h were screened at ICU admission. The minimum inhibitory concentrations (MICs) for polymyxins were determined by broth microdilution, and clonality was determined by pulsed‐field gel electrophoresis. The stepwise logistic regression was used to identify risk factors related to acquisition of PRAB, and Cox forward regression used to identify risk factors for 60‐day mortality. Results We evaluated 65 patients submitted to LT, among whom PRAB was isolated in 7, 4 of whom developed infection. The MICs for polymyxin E ranged from 16 to 128 mg/mL. All patients with PRAB required dialysis. The median time of polymyxin use before PRAB isolation was 21 days. These 4 included 1 case of primary bloodstream infection (BSI), which was treated with the carbapenem‐polymyxin combination; 1 case of surgical site infection, which was treated with gentamicin, polymyxin, ampicillin‐sulbactam, and tigecycline; and 2 cases of pneumonia, treated with the combination of carbapenem‐polymyxin. In the case of BSI and in 1 of the cases of pneumonia, the treatment was considered successful. Mortality was 71% among the cases, compared with 33% among the non‐cases. Conclusion In the final model of the survival analysis, PRAB colonization or infection after LT was independently associated with mortality. One predominant clone was identified. The only risk factor identified in the multivariate analysis was polymyxin use. PRAB was an agent with high mortality, and the most important risk factor associated with colonization or infection for such bacterium was polymyxin use.
- 12 April 2014
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (3) , 369-378
Polymyxin use as a risk factor for colonization or infection with polymyxin‐resistant Acinetobacter baumannii after liver transplantation
Introduction Acinetobacter baumannii is a leading agent of healthcare‐associated infection. The objective of this study was to evaluate cases of colonization or infection with polymyxin‐resistant A. baumannii (PRAB) in liver transplant recipients and to identify the risk factors for the acquisition of PRAB. Methods We evaluated all patients undergoing liver transplantation (LT) between January and November of 2011. The exclusion criterion was death within the first 72 h after transplant. Patients were screened for PRAB through weekly rectal and inguinal swabs during their stay in the intensive care unit (ICU) and at ICU discharge. Patients who came from other hospitals or had been treated in the emergency room for >72 h were screened at ICU admission. The minimum inhibitory concentrations (MICs) for polymyxins were determined by broth microdilution, and clonality was determined by pulsed‐field gel electrophoresis. The stepwise logistic regression was used to identify risk factors related to acquisition of PRAB, and Cox forward regression used to identify risk factors for 60‐day mortality. Results We evaluated 65 patients submitted to LT, among whom PRAB was isolated in 7, 4 of whom developed infection. The MICs for polymyxin E ranged from 16 to 128 mg/mL. All patients with PRAB required dialysis. The median time of polymyxin use before PRAB isolation was 21 days. These 4 included 1 case of primary bloodstream infection (BSI), which was treated with the carbapenem‐polymyxin combination; 1 case of surgical site infection, which was treated with gentamicin, polymyxin, ampicillin‐sulbactam, and tigecycline; and 2 cases of pneumonia, treated with the combination of carbapenem‐polymyxin. In the case of BSI and in 1 of the cases of pneumonia, the treatment was considered successful. Mortality was 71% among the cases, compared with 33% among the non‐cases. Conclusion In the final model of the survival analysis, PRAB colonization or infection after LT was independently associated with mortality. One predominant clone was identified. The only risk factor identified in the multivariate analysis was polymyxin use. PRAB was an agent with high mortality, and the most important risk factor associated with colonization or infection for such bacterium was polymyxin use.
- Open Access
- 1 January 2014
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 56 (1) , 71-76
POLYCLONAL OUTBREAK OF BLOODSTREAM INFECTIONS CAUSED BY Burkholderia cepacia COMPLEX IN HEMATOLOGY AND BONE MARROW TRANSPLANT OUTPATIENT UNITS
Aim: The objective was to describe an outbreak of bloodstream infections by Burkholderia cepacia complex (Bcc) in bone marrow transplant and hematology outpatients.
- 1 January 2014
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 56 (1) , 71-76
Open AccessPOLYCLONAL OUTBREAK OF BLOODSTREAM INFECTIONS CAUSED BY Burkholderia cepacia COMPLEX IN HEMATOLOGY AND BONE MARROW TRANSPLANT OUTPATIENT UNITS
Aim: The objective was to describe an outbreak of bloodstream infections by Burkholderia cepacia complex (Bcc) in bone marrow transplant and hematology outpatients.
- 1 August 2013
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 76 (4) , 518-520
Methicillin-resistant Staphylococcus aureus carrying SCCmec type II was more frequent than the Brazilian endemic clone as a cause of nosocomial bacteremia
- 1 August 2013
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 76 (4) , 518-520
Methicillin-resistant Staphylococcus aureus carrying SCCmec type II was more frequent than the Brazilian endemic clone as a cause of nosocomial bacteremia
- 1 December 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 65 (4) , 431-434
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
- 1 December 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 65 (4) , 431-434
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity